# A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

> **NCT01498328** · PHASE2 · COMPLETED · sponsor: **Celldex Therapeutics** · enrollment: 127 (actual)

## Conditions studied

- Glioblastoma
- Small Cell Glioblastoma
- Giant Cell Glioblastoma
- Gliosarcoma
- Glioblastoma With Oligodendroglial Component
- Recurrent Glioblastoma
- Relapsed Glioblastoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Rindopepimut (CDX-110) with GM-CSF
- **DRUG:** KLH

## Key facts

- **NCT ID:** NCT01498328
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-04
- **Final completion:** 2016-05-17
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01498328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01498328, "A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01498328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*